MedTrace Logo

Contrast-enhanced Ultrasound of the Kidney

NCT02684435 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2019-09-26

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to evaluate contrast-enhanced ultrasound for kidney malignancies

Conditions

Interventions

DRUG

Perflutren lipid microsphere

Dosing per approved package label

Sponsors & Collaborators

  • Vanderbilt University

    collaborator OTHER

  • North Carolina Translational and Clinical Sciences Institute

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Emily Chang, M.D. · University of North Carolina Kidney Center 7024 Burnett Womack CB #7155 Chapel Hill, NC 27599-7155

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-07-09
Completion
2018-07-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02684435 on ClinicalTrials.gov